Llwytho...
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Therap Adv Gastroenterol |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/ https://ncbi.nlm.nih.gov/pubmed/27582886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|